31 results about "Squamous cell carcinoma Antigen" patented technology

The invention discloses an integral detecting reacting board and protein chip agent box of Carcinoembryonic antigen,CEA, 15-3 CA15-3(Carbohydrate Antigen 15-3,CA15-3), CA 125 (Cancer antigen 125,CA125), Squamous cell carcinoma antigen,SCC, Human papillomavirus antibody,HPVAb, beta-human chorionic gonadotropin, beta-HCG and alpha-fetoprotein,AFP, wherein the reacting hole board contains base and reacting hole on the base; the reacting hole contains 2-384 sample holes, 2-200 standard sample holes; the fixing phase carrier is set on the bottom of each reacting hole, which is covered by seven antigen or antibody molecule arrays with anti-CEA, anti-CA15-3,anti-CA125,anti-SCC,HPV,anti- beta-HCG,anti-AFP.

The invention discloses a kit for predicating lung cancer risk for high-risk groups among the China urban population on the basis of CT (computed tomography) images and biomarker spectrums. The kit comprises a reagent for measuring the expression quantity of serum protein spectrums of the following four biomarkers including pro-gastrin-releasing peptides, carcino-embryonic antigens, fragments of cytokeratin 19 and squamous-cell carcinoma antigens. The kit can be used for accurately predicating the lung cancer risk in combination of CT imageology parameters including nodule diameters, spicule signs and positions and other clinical indexes including age, the smoking history, the history of malignant tumor and genders.

The present invention provides a method and composition that inhibit the kinase activity of JNK-1 (c-Jun N-terminal kinase 1) in cells by increasing the expression of squamous cell carcinoma antigen (SCCA) in cells.

The invention discloses a kit for measuring the content of a squamous cell carcinoma antigen (SCC) in human serum by a magnetic particle chemiluminescence method. The kit comprises a calibrator, a quality control, a resistant reagent, a magnetic particle reagent and a luminescent substrate. The resistant reagent comprises fluorescein isothiocyanate-labeled squamous cell carcinoma antigen-coated antibodies and alkaline phosphatase-labeled squamous cell carcinoma antigen-coated antibodies. The magnetic particle reagent is a connector of magnetic particles and goat anti-FITC. The magnetic particle is used as an immune reaction solid phase. Through combination of a chemiluminescence enzyme-linked immunoassay method and a chemiluminescence measuring instrument, the method is used for detectingthe SCC content of human serum, simultaneously measures multiple samples based on a fully automated chemiluminometer, realizes high-throughput rapid measurement of SCC, and greatly improves accuracy,specificity, precision and detection efficiency.

In a first aspect thereof, the present invention provides a method for treatment and / or prevention of a disease selected from the group consisting of psoriasis and squamous cell carcinoma by inhibiting the expression of squamous cell carcinoma antigen (SCCA) by cells. In another aspect thereof, the present invention provides a method for screening for substances that inhibit epidermal parakeratosis, wherein the activity of a candidate substance that inhibits cysteine protease inhibitory activity possessed by squamous cell carcinoma antigen 1 (SCCA-1) is used as an indicator.

The invention discloses a model for predicating lung cancer risks for people suffering from pulmonary nodules among the China urban population on the basis of CT (computed tomography) images and biomarker spectrums. The model comprises biomarkers, enzyme-labeled antibodies of the biomarkers, a carbonate buffer solution with the pH value being 9.6, a phosphate buffer solution with a pH value being 7.4, a serum protein diluent, a stop solution, a tetramethyl benzidine substrate solution, serum of normal people and positive control serum; the biomarkers are four biomarkers including pro-gastrin-releasing peptides, carcino-embryonic antigens, fragments of cytokeratin 19 and squamous-cell carcinoma antigens and are combined with CT imageology parameters and other clinical indexes. The model can assist in screening of lung cancer.

The present invention relates to monoclonal antibodies capable of distinguishing squamous cell cancer antigens, SCCA, in either free or complex bound forms, preferably antigens SCCA1 and SCCA2, as well as hybridomas recognizing such antibodies, method for diagnosing SCC, as well as diagnostic kits for detecting SCCAs.

The invention discloses a method for enhancing the luminous intensity of a squamous-cell carcinoma antigen during electrochemical luminescence detection. The method mainly comprises a construction step of an electrochemical luminescence sensor, wherein the construction step comprises: preparing an SCCA solution with certain concentration, dripping the SCCA on a polymer molecular imprinting modified electrode for incubation, performing washing with water after the incubation is completed, then dripping a Fe-MIL-88-NH2 @ZnSe / Ab / BSA complex onto the electrode and incubating the same, performing washing with water after the incubation is completed, and drying to obtain the electrochemical luminescence sensor; and the prepared electrochemical luminescence sensor is placed in a PBS buffer solution containing a co-reactant to perform electrochemical luminescence detection, and then the luminous intensity of the SCCA during the electrochemical luminescence detection can be effectively. The electrochemical luminescence sensor constructed by the method disclosed by the invention has good selectivity and high sensitivity, and when the electrochemical luminescence sensor is applied to the electrochemical luminescence detection of the SCCA, the linear range of the method is effectively increased, and the detection sensitivity is improved.

The invention discloses a biomarker spectrum-based lung cancer risk prediction model for Chinese rural residues suffering from pulmonary nodules. The lung cancer risk prediction model is composed of biomarkers and enzyme-labeled antibodies thereof, a carbonate buffer solution with the pH value of 9.6, a phosphate buffer solution with the pH value of 7.4, serum protein diluent, a stop solution, a tetramethyl benzidine substrate solution, normal human serum and positive control serum. The biomarkers comprise gastrin releasing propeptide, a carcino-embryonic antigen, fragments of cytokeratin 19 and a squamous cell carcinoma antigen and are combined with other clinical indexes. The lung cancer risk prediction model can assist in lung cancer screening.

The invention discloses a water-soluble Zn-Mg-Te quantum dot and a preparation method of a water-soluble Zn-Mg-Te quantum dot / titanium dioxide nanorod composite material, and belongs to the technicalfields of tumour marker detection, photoelectrochemistry and immune sensing. The water-soluble Zn-Mg-Te quantum dot / titanium dioxide nanorod composite material modifies an L-shaped glassy carbon electrode, the composite material is loaded with a squamous cell carcinoma antibody to form a photoelectric immunosensor, and on the basis of immunological reaction, the specificity of a squamous cell carcinoma antigen is detected by taking white light as a laser light source. The water-soluble Zn-Mg-Te quantum dots, the titanium dioxide nanorods and the white laser source are introduced into the photoelectric squamous cell carcinoma immunization sensing system, and the prepared photoelectric immunosensor has the advantages of being convenient, simple, economic, highly adaptive, simple and rapid inoperation, high in selectivity and sensitivity, and low in detecting limit.

The invention relates to a biomarker-spectrum-based lung cancer risk prediction kit for high-risk groups in rural China.The kit comprises reagents for measuring the serum protein spectrum expression quantity of the four biomarkers comprising gastrin release propeptide, the carcino-embryonic antigen, the cytokeratin 19 fragment and the squamous-cell carcinoma antigen.The kit is combined with other clinical indexes such as the age, smoking history, malignancy history and sex, and can be used for accurately predicting the lung cancer risk.

The invention relates to an in-situ hybridization detection kit for SCCA1 (squamous cell carcinoma antigen 1) genes, which comprises a hybridization probe and a marker, wherein the sequence of the hybridization probe is expressed as SEQ ID No.1. The invention also provides an in-situ hybridization detection method for the SCCA1 genes. In addition, the invention also provides application of the kit in preparation of a medicament for detecting liver cancer diseases. The kit provided by the invention has the advantages of high sensitivity and strong specificity. The detection method is convenient and simple to operate, and can be universally used and popularized in hospitals of above district level.

The invention provides a chemiluminescent immunoassay quantitative detection kit for squamous cell carcinoma antigens, which relates to the medical field of immunoassay. The kit of the invention is mainly composed of a squamous cell carcinoma antigenic temporary calibrator, a solid-phase vector which is coated by a squamous cell carcinoma antigenic antibody, a squamous cell carcinoma antigenic antibody which is marked by enzyme, a chemiluminescent substrate solution and a concentrated washing solution. The preparation method of the kit mainly comprises the following steps: the coating of the solid-phase vector, the preparation of the calibrator and enzyme markers and the preparation of the chemiluminescent substrate solution and the concentrated washing solution. With the kit and the preparation method thereof, the detection sensitivity, the linear range and the quantitative accuracy can be improved. The invention has convenient use, safety and stability.

The present invention provides a method for evaluating the degree of skin sensitivity by using the expression of squamous cell carcinoma antigen (SCCA) in skin corneocytes as an indicator thereof.

The invention belongs to the technical field of biomedical detection and particularly relates to a marker for cervical cancer detection and a detection kit. The marker comprises a squamous cell carcinoma antigen, a carcino-embryonic antigen, a carbohydrate antigen 125, a carbohydrate antigen 199 and a human epididymal protein 4, acridinium ester is adopted for direct chemiluminescence, an antibody (antigen) is directly labeled with acridinium ester, after immunoreaction with a corresponding antigen (antibody) of a sample to be detected, a coated antibody-antigen to be detected-acridinium ester labeled antibody compound is formed, excitation liquid is added, and decomposition and luminescence can be achieved without a catalyst. A combination of multiple tumor markers is established, detection specificity and sensitivity of cervical cancer are improved through combined detection of multiple indexes, detection sensitivity and accuracy are high when serum detection is carried out on a cervical cancer patient, combined detection can have a high detection rate on tumors, and early screening, treatment effect and postoperative recurrence of cervical cancer patients can be dynamically monitored.

The invention provides a squamous cell carcinoma antigen detection reagent. The squamous cell carcinoma antigen detection reagent comprises magnetic microspheres coating squamous cell carcinoma antigen antibodies, squamous cell carcinoma antigen antibodies labeled by alkaline phosphatase, and a chemiluminescent substrate; and the magnetic microspheres are silicon dioxide magnetic composite particles. The squamous cell carcinoma antigen detection reagent provided by the invention has the advantages of simple components and high detection sensitivity, and can realize rapid and accurate detectionin a short time.

The present invention relates to a SCCA1 / SCCA2 fusion protein; plasmid containing the same; antibodies of said fusion protein; methods for detecting said protein; methods for diagnosing the presence or absence of SCC by determining the presence of SCCA1 / SCCA2 fusion protein.

The invention discloses a kit for predicating lung cancer risk for high-risk groups among the China urban population on the basis of CT (computed tomography) images and biomarker spectrums. The kit comprises a reagent for measuring the expression quantity of serum protein spectrums of the following four biomarkers including pro-gastrin-releasing peptides, carcino-embryonic antigens, fragments of cytokeratin 19 and squamous-cell carcinoma antigens. The kit can be used for accurately predicating the lung cancer risk in combination of CT imageology parameters including nodule diameters, spicule signs and positions and other clinical indexes including age, the smoking history, the history of malignant tumor and genders.

The invention discloses a cell carcinoma antigen hybridoma cell strain and an application method of a monoclonal antibody of the cell carcinoma antigen hybridoma cell strain. The antibody for detecting SCC is an antigen polypeptide sequence specifically designed according to the sequence characteristics of SCCA1 and SCCA2, and is used as an antigen to immunize BALB / c mice, a hybridoma cell strain4H8 for generating the antibody is obtained by using a cell fusion technology, and the antibody secreted by hybridoma cells is IgG1 positive; the invention provides the hybridoma cell strain secretingthe monoclonal antibody, the preservation number of the hybridoma cell strain is CCTCC NO: C2019315, and the hybridoma cell strain can stably secrete a high-titer monoclonal antibody for resisting squamous cell carcinoma antigen. An immune reagent developed by using the squamous cell carcinoma antigen-antibody provided by the invention can accurately determine squamous cell carcinoma antigens ina serum sample, can simultaneously detect SCCA1 and SCCA2, has high sensitivity and accuracy, has high correlation with detection results of imported reagents sold on the market, and can replace imported antibodies, so that the production cost is reduced.

The invention discloses a lung cancer risk prediction model based on CT images and biomarker spectrum for Chinese urban population with pulmonary nodules. Phosphate buffer solution with a value of 7.4, serum protein dilution, stop solution, tetramethylbenzidine substrate solution, normal human serum and positive control serum; the biomarkers include gastrin-releasing propeptide, Four biomarkers including carcinoembryonic antigen, fragment of cytokeratin 19 and squamous cell carcinoma antigen were combined with CT imaging parameters and other clinical indicators. The present invention can assist in screening for lung cancer.

The present invention relates to a SCCA1 / SCCA2 fusion protein; plasmid containing the same; antibodies of said fusion protein; methods for detecting said protein; methods for diagnosing the presence or absence of SCC by determining the presence of SCCA1 / SCCA2 fusion protein.

The invention relates to a biomarker-spectrum-based lung cancer risk prediction kit for high-risk groups in rural China.The kit comprises reagents for measuring the serum protein spectrum expression quantity of the four biomarkers comprising gastrin release propeptide, the carcino-embryonic antigen, the cytokeratin 19 fragment and the squamous-cell carcinoma antigen.The kit is combined with other clinical indexes such as the age, smoking history, malignancy history and sex, and can be used for accurately predicting the lung cancer risk.

The invention relates to a magnetic bead supporting substrate method for capturing cervical cancer proteome in biological sample in vitro, which uses magnetic separator to separate magnetic bead and sample, without centrifugation of samples. Then fingerprint technique is used to analyze protein with mass spectrometry method. The invention can be used in kits for testing squamous cell carcinoma negative antigen cervical cancer sample and normal person in vitro and for protein fingerprint or mass spectrometry polypeptide mapping of prognosis. The method is accurate, convenient and fast.

In a first aspect thereof, the present invention provides a method for treatment and / or prevention of a disease selected from the group consisting of psoriasis and squamous cell carcinoma by inhibiting the expression of squamous cell carcinoma antigen (SCCA) by cells. In another aspect thereof, the present invention provides a method for screening for substances that inhibit epidermal parakeratosis, wherein the activity of a candidate substance that inhibits cysteine protease inhibitory activity possessed by squamous cell carcinoma antigen 1 (SCCA-1) is used as an indicator.

The invention relates to a squamous cell carcinoma antigen measurement system, which includes magnetic beads coated by an anti-fluorescein isothiocyanate antibody, a squamous cell carcinoma antigen antibody marked by the fluorescein isothiocyanate, a squamous cell carcinoma antigen antibody marked by N-(aminobutyl)-N-(isoluminol), a chemical luminescent substrate and a fluorescent detection device. The squamous cell carcinoma antigen antibody marked by the fluorescein isothiocyanate, the squamous cell carcinoma antigen antibody marked by the N-(aminobutyl)-N-(isoluminol) and a to-be-test substance form a bis-antibody sandwich composite. The magnetic beads coated by the anti-fluorescein isothiocyanate antibody is used for being combined with the bis-antibody sandwich composite to form an antigen antibody composite precipitate which is subjected to a fluorescent reaction with the chemical luminescent substrate. The fluorescent detection device is used for detecting fluorescent intensity of the fluorescent reaction. The squamous cell carcinoma antigen measurement system does not contain any radioactive substances, is high in sensitivity, is good in specificity and is high in accuracy.

The invention discloses a method for enhancing the luminescence intensity of squamous cell carcinoma antigen in electrochemiluminescence detection, which mainly includes the construction step of electrochemiluminescence sensor. Add dropwise to the polymer molecularly imprinted modified electrode for incubation, wash with water after incubation, and then add Fe‑MIL‑88‑NH dropwise on the electrode 2 @ZnSe / Ab / BSA complex and incubate, wash with water after incubation, and dry to form an electrochemiluminescence sensor; use the electrochemiluminescence sensor prepared above to place in PBS buffer containing co-reactants for electrochemiluminescence Detection can effectively enhance the luminescence intensity of SCCA in electrochemiluminescence detection. The electrochemiluminescence sensor constructed by the invention has good selectivity and high sensitivity, and when it is used for electrochemiluminescence detection of SCCA, the linear range of the method is effectively increased and the detection sensitivity is improved.

The invention relates to the field of biotechnology, and discloses new applications of CCAT2, LINC00511 and LINC01133 among long-chain non-coding RNAs in the field of cervical cancer diagnosis. The present invention found that the expression of CCAT2, LINC00511 and LINC01133 in the serum of cervical cancer increased, and they are potential cervical cancer diagnostic markers. They are combined with squamous cell carcinoma antigen (SCC) as tumor markers for joint diagnosis, and have stronger specificity and sensitivity. Therefore, The present invention provides a new application of CCAT2, LINC00511 and LINC01133 and the combination of the three and SCC in the field of cervical cancer diagnosis, thereby providing a new diagnostic method for diseases in this field, and also supplementing the three of CCAT2, LINC00511 and LINC01133 Research results.